Matrix metalloproteinases: old dogs with new tricks

gb-2003-4-6-216 GBJ Review Matrix metalloproteinases: old dogs with new tricks Somerville PT Robert Oblander A Samantha Apte S Suneel aptes@bme.ri.ccf.org

Department of Biomedical Engineering, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA

Genome Biology 1465-6906 2003 4 6 216 http://genomebiology.com/2003/4/6/216 10.1186/gb-2003-4-6-216 12801404 29 5 2003 2003 BioMed Central Ltd

It was previously thought that the matrix metalloproteinase family acted only to degrade components of the extracellular matrix, but this view has changed with the discovery that non-extracellular-matrix molecules are also substrates.

Abstract

The matrix metalloproteinase family in humans comprises 23 enzymes, which are involved in many biological processes and diseases. It was previously thought that these enzymes acted only to degrade components of the extracellular matrix, but this view has changed with the discovery that non-extracellular-matrix molecules are also substrates.

Cell biology Biochemistry and structural biology Cancer Genetics

Four decades ago a collagenase was discovered that was responsible for involution of the tadpole tail in amphibian morphogenesis 1. Today, the matrix metalloproteinase (MMP) family, to which this collagenase belongs, has expanded to include 23 gene products in humans (Table 1), which encode zinc-dependent and calcium-dependent proteases that cleave within a polypeptide (endopeptidases). There are also two other large families that have major roles in extracellular proteolysis, the ADAM family (A disintegrin and metalloprotease domain, with about 33 members in humans) and the ADAMTS family (A disintegrin-like and metalloprotease domain (reprolysin type) with thrombospondin type I repeats, with 19 members). Traditionally, the MMPs have always been thought to cleave components of the extracellular matrix (ECM). As the ECM was regarded for a long time as nothing more than a passive structure used for cell attachment, mechanical support and force transmission, extracellular proteases such as MMPs were thought to simply remodel the ECM for its homeostasis or to facilitate cell migration. This view has changed, however 2: the ECM is now known to contain growth factors, their binding proteins, and other bioactive molecules, as well as binding sites for cell-surface molecules, some of which are revealed only after proteolysis. The proteases responsible for turnover of the ECM therefore contribute significantly to its dynamic interactions with cells. More recently, considerable evidence has emerged showing that the role of MMPs goes far beyond that of digesting ECM molecules alone; they are now known to process a number of cell-surface and soluble regulators of cell behavior (summarized in Table 1). Mouse genetic models and human diseases have revealed unexpected biological functions of MMPs (summarized in Table 2); many of the phenotypes of these animals are currently unexplained and suggest that there may be as yet unknown substrates for these enzymes that are not ECM components.

Table 1

Human matrix metalloproteases and their substrates

Protein name*

Alternative names

Collagenous substrates

Non-collagenous ECM substrates

Non-structural ECM component substrates

MMP-1

Collagenase-1

Collagen types I, II, III, VII, VIII, X, and gelatin

Aggrecan, casein, nidogen, serpins, versican, perlecan, proteoglycan link protein, and tenascin-C

α₁-antichymotrypsin, α₁-antitrypsin/α₁-proteinase inhibitor, IGFBP-3, IGFBP-5, IL-1β, L-selectin, ovostatin, recombinant TNF-α peptide, and SDF-1

MMP-2

Gelatinase-A

Collagen types I, IV, V, VII, X, XI, XIV, and gelatin

Aggrecan, elastin, fibronectin, laminin, nidogen, proteoglycan link protein, and versican

Active MMP-9, active MMP-13, FGF R1, IGF-BP3, IGF-BP5, IL-1β, recombinant TNF-α peptide, and TGF-β

MMP-3

Stromelysin-1

Collagen types II, IV, IX, X, and gelatin

Aggrecan, casein, decorin, elastin, fibronectin, laminin, nidogen, perlecan, proteoglycan, proteoglycan link protein, and versican

α₁-antichymotrypsin, α₁-proteinase fibrinogen, IGF-BP3, L-selectin, ovostatin, pro-HB-EGF, pro-IL-β, pro-MMP-1, pro-MMP8, pro-MMP-9, pro-TNFα, and SDF-1

MMP-7

Matrilysin-1, neutophil collagenase

Collagen types I, II, III, V, IV, and X

Aggrecan, casein, elastin, enactin, laminin, and proteoglycan link protein

β₄integrin, decorin, defensin, E-cadherin, Fas-L, plasminogen, pro-MMP-2, pro-MMP-7, pro-TNFα, transferrin, and syndecan

MMP-8

Collagenase-2

Collagen types I, II, III, V, VII, VIII, X, and gelatin

Aggrecan, laminin, and nidogen

α₂-antiplasmin and pro-MMP-8

MMP-9

Gelatinase-B

Collagen types IV, V, VII, X, and XIV

Fibronectin, laminin, nidogen, proteoglycan link protein, and versican

CXCL5, IL-1β, IL2-R, plasminogen, pro-TNFα, SDF-1, and TGF-β

MMP-10

Stromelysin-2

Collagen types III, IV, V, and gelatin

Fibronectin, laminin, and nidogen

Pro-MMP-1, pro-MMP-8, and pro-MMP-10

MMP-11

Stromelysin-3

Laminin

α₁-antitrypsin, α₁-proteinase inhibitor, and IGFBP-1

MMP-12

Macrophage metalloelastase

Elastin

Plasminogen

MMP-13

Collagenase-3

Collagen types I, II, III, IV, V, IX, X, XI, and gelatin

Aggrecan, fibronectin, laminin, perlecan, and tenascin

Plasminogen activator 2, pro-MMP-9, pro-MMP-13, and SDF-1

MMP-14

MT1-MMP

Collagen types I, II, III, and gelatin

Aggrecan, dermatan sulphate proteoglycan, fibrin, fibronectin, laminin, nidogen, perlecan, tenascin, and vitronectin

α_vβ₃integrin, CD44, gC1qR, pro-MMP2, pro-MMP-13, pro-TNFα, SDF-1, and tissue transglutaminase

MMP-15

MT2-MMP

Collagen types I, II, III, and gelatin

Aggrecan, fibronectin, laminin, nidogen, perlecan, tenascin, and vitronectin

Pro-MMP-2, pro-MMP-13, and tissue transglutaminase

MMP-16

MT3-MMP

Collagen types I, III, and gelatin

Aggrecan, casein, fibronectin, laminin, perlecan, and vitronectin

Pro-MMP-2 and pro-MMP-13

MMP-17

MT4-MMP

Gelatin

Fibrin and fibronectin

MMP-19

RASI-1

Collagens types I, IV, and gelatin

Aggrecan, casein, fibronectin, laminin, nidogen, and tenascin

MMP-20

Enamelysin

Aggrecan, amelogenin, and cartilage

MMP-21

α₁-antitrypsin

MMP-23

CA-MMP

Gelatin

MMP-24

MT5-MMP

Gelatin

Chondroitin sulfate, dermatin sulfate, and fibronectin

Pro-MMP2 and pro-MMP-13

MMP-25

Leukolysin, MT6-MMP

Collagen type IV and gelatin

Fibrin and fibronectin Pro-MMP-2

MMP-26

Matrilysin-2, endometase

Collagen type IV and gelatin

Casein, fibrinogen, and fibronectin

β₁-proteinase inhibitor

MMP-28

Epilysin

Casein

*Although there are 23 human MMPs, 29 numbers have been used in the literature. The symbols MMP-4, MMP-5, MMP-6 and MMP-29 are redundant in humans and are no longer in use; MMP-18 corresponds to a Xenopus laevis collagenase, for which no human ortholog is known, and a human protein published as MMP-18 is now called MMP-19. Two nearly identical human genes found in a segment of chromosome 1 that is duplicated were called MMP21 and MMP22 but are now referred to as MMP23A and MMP23B.

Table 2

Phenotypes of knockout mice lacking MMP genes

Genotype

Phenotype

MMP2 ^-/-

Suppression of experimentally induced pancreatic carcinogenesis 85; suppression of angiogenesis and tumor growth 86; delayed mammary gland differentiation; mild growth retardation.

MMP3 ^-/-

Accelerated mammary gland adipogenesis 87; delayed incisional wound healing 88; resistance to contact dermatitis 89; impaired ex vivo herniated disc resorption 90.

MMP7 ^-/-

Suppression of experimental adenoma growth 91; defective innate intestinal immunity 70; impaired tracheal wound re-epithelization 92; defective prostate involution after castration 93; impaired ex vivo herniated disc resorption 94; impaired transepithelial migration of neutrophils 32; reduced syndecan-1 shedding 32.

MMP9 ^-/-

Suppression of experimentally induced skin carcinogenesis 95; suppression of experimentally induced pancreatic carcinogenesis 85; decreased experimental metastasis 86; delayed growth plate vascularization 96; abnormal endochondral ossification 96; defective in osteoclast recruitment 97; resistance to bullous pemphigoid (skin blistering) 98; resistance to experimentally induced aortic aneurysms 99; prolonged contact dermatitis 89; protection from ventricular enlargement after infarction 100; protection from cardiac rupture after infarction 101; diminished peripheral mononucleocyte infiltrate in glomerular nephritis 102; impaired smooth muscle cell migration and geometrical arterial remodeling 103104; impaired cellular infiltration and bronchial hyper-responsiveness during allergen-induced airway inflammation 105; impaired recruitment of stem and progenitor cells from the bone marrow following irradiation 106; myocardial protection from ischemia and/or reperfusion 107.

MMP11 ^-/-

Suppression of experimentally induced mammary carcinogenesis 108; decreased tumor cell survival and growth 109; accelerated neointima formation after vessel injury 110.

MMP12 ^-/-

Resistance to cigarette-smoke-induced emphysema 111.

MMP14 ^-/-

Severe abnormalities in bone and connective tissue 7677; reduced collagen turnover 76; impaired endochondral ossification 7677; defective angiogenesis 7677.

Data in the table are modified from 57783112.

One consequence of the previously held view of MMPs as solely ECM-excavating enzymes was the belief that they were uniformly harmful in cancer and should therefore be targeted in cancer therapy. This was not entirely without basis, given that many MMPs are highly expressed in various cancers, both by tumor cells and in surrounding stromal cells such as macrophages. As recent reviews 3456 have pointed out, however, the unexpectedly complex role of these enzymes in cancer is leading to their re-evaluation as drug targets, or at the very least, a pause while some of the evidence is analyzed in more detail. Although this is disappointing from the clinical perspective, the study of these enzymes has never been more exciting than it is today, because the human genome project has led to identification of all MMPs, and genetic alterations in individual MMP genes have provided new insights into their functions. In this article, we summarize some of the essential concepts in the MMP field at present and the new insights that are pouring in from biological studies.

Classification and evolution

There are 23 human MMP genes (Table 1). Before this genetic diversity was known, it was customary to divide the MMPs into collagenases, gelatinases, stromelysins, elastase and others, on the basis of the known substrates, but as some MMPs have overlapping substrate specificities, the boundary between the previously used enzyme classes is now blurred. Nevertheless, the trivial names are often useful, particularly if they reflect a function or a distinct structural feature or location, and they have therefore been retained (and are indicated in Table 1). MMP genes are structurally similar to each other, indicating that they evolved by duplication of a common ancestral gene followed by divergent evolution. A number of MMP genes (MMP1, MMP3, MMP7, MMP8, MMP10, MMP12, MMP13, MMP20, and MMP26) are found in a cluster on human chromosome 11 (11q21-23) 78. The human and mouse genomes appear not to contain an identical complement of MMPs, which may complicate the use of transgenic mice for insights into functions of the human genes. For example, human MMP1 does not have a clear-cut ortholog in the mouse but instead is most similar to two genes, mColA and mColB, whose functions are at present unknown 9.

MMP genes have been identified in a number of non-vertebrate species, and the number will undoubtedly increase as more genome projects are completed. The nematode Caenorhabditis elegans has a number of MMPs, including C31, H19 and Y19 10; there is a Drosophila MMP 11; sea urchins contain an MMP essential for hatching, known as envelysin 12; and the hydra has an MMP that is required for foot-process development 13. Interestingly, there is an MMP in green algae 14 as well as in plants such as the soybean 15 and Arabidopsis thaliana 16.

Domain organization and protein structure

The close evolutionary relationship between MMPs is further reflected in the conservation of their domain structure (Figure 1) and of their mechanisms of catalysis and regulation. Most MMPs are secreted, although some are anchored to the cell surface by a transmembrane segment (MMP-14, MMP-15, MMP-16 and MMP-24, referred to as membrane-type MMPs or MT-MMPs) 17 or via a glycosylphosphoinositol (GPI) anchor (MMP-17 and MMP-25, sometimes also included in the MT-MMPs) 18. Most of the MT-MMPs are type I transmembrane proteins - oriented with the amino terminus outside the cell - although one, MMP-23, is unusual in apparently having the amino terminus positioned intracellularly (a type II orientation) 19. The MT-MMPs have a single transmembrane domain followed by a short, highly conserved cytosolic segment of 20 amino acids. 'Soluble' MMPs may also be located at the cell surface via interaction with membrane-bound molecules or complexes such as integrin α_vβ₃20, the extracellular matrix metalloproteinase inducer EMMPRIN/CD147 21, the hyaluronan receptor CD44 22, cell-surface heparan-sulfate proteoglycans such as syndecans 23, or transmembrane MMPs 17.

Figure 1

The domain composition and important structural features of the various subtypes of MMPs

The domain composition and important structural features of the various subtypes of MMPs.

All MMPs except MMP-7 (matrilysin-1) and MMP-26 (endometase or matrilysin-2) consist of two domains connected by a flexible proline-rich hinge peptide. The domains comprise a protease domain and an ancillary (helper) domain - most commonly a domain similar to sequences in the heme-binding protein hemopexin and the soluble fibronectin-related protein vitronectin 2425 (see Figure 1). The protease domain contains a signal peptide, the pro-domain, and the catalytic module, in that order. MMP-2 and MMP-9, which are the main gelatinases, differ from other MMPs in that they have three tandem fibronectin type II repeats within the amino terminus of the catalytic module that mediate gelatin binding (Figure 1c) 262728. MMP-9 has an additional insert within its hinge region similar to collagen V; its function is unknown. MMP-7 and MMP-26 29 lack the hemopexin/vitronectin-like domain (Figure 1a), whereas MMP-23 has a unique cysteine- and proline-rich sequence and a domain similar to the immunoglobulin-like domains of the interleukin-1 receptor instead of the hemopexin/vitronectin-like domain (Figure 1g) 30.

X-ray crystal structures are now available for a number of MMPs, including full-length activated enzymes and zymogen forms that include the pro-domain 31. Crystallography has revealed how a cleft in the active site contributes to enzyme specificity 32. The catalytic domain of all MMPs has a unique signature of amino-acid residues (His-Glu-X-Gly-His-X-X-Gly-X-X-His-Ser, where X is any amino acid) within the active site 25 that coordinates the catalytic zinc atom. The hemopexin/vitronectin-like domain consists of four parts arranged symmetrically around a central axis, forming a four-bladed propeller-like structure that helps to confer substrate-binding specificity on the enzyme.

Regulation of MMPs

In keeping with their potential for tissue destruction, MMPs are stringently regulated at multiple levels, including transcription, activation of the zymogen forms, extracellular inhibitors, location inside or outside the cell and internalization by endocytosis. The pro-domain keeps the enzyme latent using the thiol group of a highly conserved, unpaired cysteine at its carboxyl terminus. This conserved cysteine acts as a fourth inactivating ligand for the catalytic zinc atom in the active site, resulting in the exclusion of water and rendering the enzyme inactive (Figure 2). For the enzyme to be activated, this cysteine-zinc pairing needs to be disrupted by a conformational change or by proteolysis (such as by the protease plasmin or by other MMPs). Once the thiol group is replaced by water, the enzyme is able to hydrolyze the propeptide to complete the activation process and can then cleave the peptide bonds of its substrates. This system of regulation is referred to as the 'cysteine-switch' mechanism 33. Most MMPs are not activated until they are outside the cell, but the MT-MMPs and MMP-11, MMP-23 and MMP-28 are activated by a proprotein convertase (such as furin) within the secretory pathway 34353637.

Figure 2

The 'cysteine-switch' mechanism regulating the MMP zymogen

The 'cysteine-switch' mechanism regulating the MMP zymogen. The thiol group of a conserved cysteine (C) at the carboxyl terminus of the pro-domain acts as a fourth inactivating ligand for the catalytic zinc atom in the active site; this results in the exclusion of water and keeps the enzyme latent. Displacement of the pro-domain by conformational change or proteolysis disrupts this cysteine-zinc pairing and the thiol group is replaced by water. The enzyme can then cleave the peptide bonds of its substrates.

Once activated, there are multiple mechanisms that can inactivate the MMPs 38. Four classes of metalloproteinase inhibitors are found in extracellular spaces and body fluids that have broad inhibitory activity against many MMPs. One class is the tissue inhibitors of metalloproteinases (TIMPs), which are disulfide-bonded proteins of 20-30 kDa that directly interact with the MMP active site through a small number of their amino acids. An unrelated small inhibitor derived by proteolysis of the procollagen C-proteinase enhancer has structural similarity to TIMPs and may inhibit MMPs through a similar mechanism 39. Recently, a membrane-anchored molecule, reversion-inducing cysteine-rich protein with Kazal motifs (RECK), has been discovered that appears to regulate MMP-2, MMP-9 and MMP-14 post-transcriptionally by affecting secretion and activation as well as by inhibition of the active site 40. In the circulation, the protease inhibitor α2-macroglobulin inactivates active MMPs by a 'bait and trap' mechanism 3841: when protease-sensitive sites within the inhibitor are cleaved, it springs closed around the proteinase and isolates it from potential substrates.

MMP zymogens can also be activated by MMPs themselves; for example, MMP-2 is activated by MT-MMPs such as MMP-14 17. Paradoxically, the inhibitor TIMP-2 is absolutely required for this process, which requires it to bind to the active site of MMP-14 and also, through its carboxy-terminal domain, to the hemopexin/vitronectin-like domain of MMP-2. The essential role of TIMP-2 is emphasized by the lack of pro-MMP-2 activation in Timp2-null mice 42 as well as by the exquisite co-regulation of the Mmp14 and Timp2 genes (but not other TIMP genes) during mouse development 43. (MMP-14 also activates MMP-13 at the cell surface, but this does not seem to require TIMP-2 44.) The further activation of MMP-2 bound to TIMP2 probably involves complex but highly regulated repositioning of membrane-bound MMPs through their cytoplasmic tails or transmembrane domains or through interaction with cellular receptors. Lehti et al. 4546 have suggested that oligomerization may occur between the cytoplasmic domains of the two MMP-14 molecules, an observation that ties in with a report that a conserved cysteine in the MMP-14 cytoplasmic tail is essential for dimerization 47.

In addition to a possible role in oligomerization, the cytoplasmic domain of MT-MMPs is essential for regulating the activity of these enzymes; it acts by altering their spatial distribution in the cell in response to intracellular signaling events. The cytoplasmic sequence targets the MT-MMPs to specific domains within the cell membrane, including invadopodia (surface protrusions of invasive cells) 48 and caveolae (specialized membrane invaginations) 49. Recently, a role for the cytoplasmic domain has been identified in the cycling of MT-MMPs between an intracellular pool and the cell surface via clathrin-coated pits and vesicles 5051; this may be one of several cellular mechanisms by which the amount of enzyme at the cell surface is regulated. Studies of thrombospondin-2 null mice have indicated that thrombospondin-2 has a role in targeting active MMP-2 to the scavenger-receptor pathway 52, and it has been shown that MMP-13 binds to a specific cell-surface receptor before it is internalized via the low-density lipoprotein receptor 53.

Functions of MMPs

The substrates of MMPs are given in Table 1, and the functions of MT-MMPs in particular are illustrated in Figure 3.

Figure 3

The locations of MT-MMPs

The locations of MT-MMPs. (a) The location of MT-MMPs lends them critical biological roles at the cell surface: they cleave components of the ECM, other MMPs and receptors for growth factors (which leads to shedding of the receptors from the cells). (b) Mobilization of MT-MMPs to the leading edge of cancer cells, where they remodel the ECM, facilitates cell migration and tumor invasion.

Enzyme-substrate co-localization and interactions

The collagenases MMP-1, MMP-8, MMP-13, and MMP-14 are the only MMPs that can efficiently degrade the fibrillar collagens (types I, II and III) in their triple-helical domains 54. Cleavage by these enzymes renders the collagen molecules thermally unstable, so that they unwind to form gelatin, after which they can be degraded by other members of the MMP family such as the major gelatinases MMP-2 and MMP-9. The collagenase active site is unable to accommodate the entire cross-section of the collagen triple helix, an observation that has generated much interest in how this substrate is actually cleaved.

The two major gelatinases, MMP-2 and MMP-9, have several distinctive features. They can be distinguished by the fact that MMP-2 binds preferentially to TIMP-2, which is required for its activation, whereas MMP-9 is preferentially inhibited by TIMP-1 38. MMP-2 becomes located at the cell surface by binding of its carboxyl terminus to the integrin α_vβ₃29 or the MMP-14-TIMP-2 complex; when bound, the catalytic site of MMP-2 is exposed and can be cleaved and activated. The α2 chains of collagen IV bind MMP-9 with a high affinity even when MMP-9 is inactive 55; this juxtaposition of enzyme and substrate means that a pool of the enzyme is rapidly available upon activation for any remodeling events.

Non-matrix substrates and consequences of MMP activity

The extracellular matrix contains sites that can bind growth factors, either directly and via growth-factor-binding proteins. When bound, growth factors - such as transforming growth factor β (TGF-β), fibroblast growth factor 1 (FGF-1) and insulin-like growth factor 1 (IGF-1), tumor necrosis factor α, and heparin-binding epidermal growth factor-like growth factor (HB-EGF) 56 - are unable to bind their receptors and signal to the nucleus 5758596061. Several MMPs are able to release growth factors by cleaving either the growth-factor-binding protein or the matrix molecule to which these proteins attach. In addition, MMP-3 and MMP-7 can cleave the adherens-junction protein E-cadherin, thus promoting cell invasion by disrupting cell aggregation 6263. MMP-3 can release a soluble form of the adhesion molecule L-selectin 64 from leukocytes. It also sheds membrane-bound HB-EGF, so that it can exert signaling functions 56. MMP-7 releases soluble Fas ligand; this occurs during involution of the prostate after castration and induces apoptosis 65. In contrast to the activation of growth factors by proteolytic release, many growth factors are proteolytically inactivated by MMPs, including the chemoldne connective tissue activating peptide III (CTAP-III), monocyte chemoattractant protein and stromal cell-derived factor 1 (SDF-1) 6667. A second mechanism by which growth factors and cytoldnes are negatively regulated is when MPPs cause the shedding of their receptors from the cell membranes, as in the case of surface FGF receptor 1 68.

The immune system is also influenced by MMPs. Firstly, the defensins are a family of polar antimicrobial peptides that make up part of the innate immune system of some animals. Defensins are synthesized in an inactive form and activated by the proteolytic removal of the pro-domain by MMP-7, which allows them to insert into the bacterial membrane and disrupt its integrity 6970. Secondly, MMP-3 (stromelysin-1) and MMP-7 (matrilysin-1) can cleave all immunoglobulin G proteins; this cleavage is important as it prevents the initiation of the complement cascade and is potentially beneficial in the removal of the immunoglobulin G from damaged or inflamed tissue 71. And finally, the receptor of the complement component C1q, gC1qR, exists in both a membrane-bound form and a soluble form that may inhibit the hemolytic activity of C1q. By releasing gC1qR, MT1-MMP may help tumor cells to avoid targeted destruction by the complement system and may thus facilitate tumor-cell survival 727374.

Genetic alterations in human and mouse MMPs

An extensive body of literature indicates an association of MMPs with cancer, arthritis, numerous other inflammatory or autoimmune disorders, cardiovascular and cerebrovascular diseases, and fibrotic diseases. Despite this, there are relatively few instances in which MMPs have proved to be the primary cause of disease. One of these is a rare inherited disorder of bone (nodulosis arthropathy osteolysis syndrome), one of a set of 'vanishing bone syndromes', in which there is severe resorption and destruction of bones, primarily those of the hands and feet 75. The affected individuals also have chronic arthritis and subcutaneous nodules in the hands and feet. The disease is inherited in an autosomally recessive manner, and loss-of-heterozygosity analysis mapped the responsible gene to 16q12-q22, an interval containing the MMP2 gene. Analysis of the serum and fibroblasts of affected individuals showed a complete absence of MMP2. The family was found to have two homoallelic MMP2 mutations, resulting in the ablation of MMP2 activity. The presence of collagenous nodules fits with the role of MMPs in removing excess ECM; the paradox in these patients, however, is that excessive destruction of bones and arthritis are caused by an absence of a destructive enzyme, not an excess as might have been expected. There are a number of mechanisms by which this may occur: there may be compensatory overproduction of another MMP or protease, MMP-2 may be essential for processing of an inductive factor required for the activity of bone-forming cells (osteoblasts), or it may be required to regulate the activity of bone-degrading cells (osteoclasts) in tissues. Interestingly, the Mmp2 knockout mouse is not known to recapitulate the human disease, which resembles more closely the phenotype of Mmp14 knockout mice 7677. Given that MMP-14 and TIMP-2 are required for MMP-2 activation, it is possible that mutations in the genes encoding these enzymes may result in a similar human disease.

The chromosome 1p36.3 region that contains the two closely related MMP23 genes (see Table 1) is altered or frequently deleted in neuroblastomas in which the oncogene MYCN has been amplified, in a subset of malignant melanomas and in a 1p35 deletion disorder 78, but the role of the two MMP genes in these disorders has not been investigated.

A polymorphism in the MMP1 promoter can result in one allele having a sequence of either one or two guanines in a particular position. The presence of two guanines results in the de novo appearance of a binding site for the ETS-1 transcription factor that cooperates with an adjacent site for the AP-1 transcription factor to enhance the expression of MMP1 798081. It is interesting to note that cancer patients, on average, have a higher incidence of the two-guanine allele than have people in the unaffected population. A regulatory polymorphism is also present in the MMP3 promoter, leading to the presence of either five or six adenosines 82. The allele with six (6A) has a reduced transcriptional activity compared to the allele with five. A study on patients with coronary artery atherosclerosis revealed that patients homozygous for the 6A allele showed a more rapid progression of both global and focal atherosclerotic lesions.

The creation of transgenic mice that are null for specific genes has been useful in attributing functions to a number of MMP family members (Table 2). In general, most MMP gene knockouts are viable, with subtle phenotypic differences from their wild-type counterparts 83. This could reflect either a lack of function in vital developmental processes or a significant amount of redundancy amongst these enzymes for substrates, with the consequence that other family members can be upregulated to compensate for the loss of an individual enzyme. Although the lack of a dramatic phenotype in many of the knockout mice may initially have seemed a disappointing outcome, it has in fact been very valuable for dissecting the role of MMPs in cancer and inflammation. The exception to the rule is the Mmp14-knockout mouse 7677, which has severe postnatal growth-retardation and skeletal anomalies and dies before the onset of sexual maturity (Figure 4). The severity of the Mmp14 knockout, in contrast to the other MMP knockout animals, may reflect the position of this enzyme as an initiator of a number of proteolytic cascades, as well as its obligate location at the cell surface. (Note that none of the other MT-MMPs has yet been inactivated in mice.) The defects seen in these animals are probably attributable to both deficiencies in the turnover of direct MMP-14 substrates and abnormalities in the indirect substrates that are mediated by the activation of intermediary enzymes such as MMP-2 and MMP-13.

Figure 4

The phenotype of Mmp14-null mice, which is the most dramatic developmental phenotype of all MMP null transgenes

The phenotype of Mmp14-null mice, which is the most dramatic developmental phenotype of all MMP null transgenes. A rare example of an Mmp14-null mouse that has survived to 10 weeks of age is shown (front, alongside a normal littermate); note the severe dwarfism and craniofacial anomalies.

The importance of MMPs in physiological processes and human disease is now undisputed. What is not known, however, is the full extent to which they are involved in every process in mammals. The failure of broad-spectrum and even relatively specific MMP inhibitors in cancer therapy is not surprising, because the complete effects for a given inhibitor depend on the functions of its targets, and these are mostly unidentified and unknown. The fact that there are two other large families of related proteases with important physiological functions, the ADAM and ADAMTS families, suggests that additional caution should be taken when using MMP inhibitors to treat disease states. More subtle approaches are going to be required to modulate the functions of these enzymes in a more selective fashion 84. By understanding the precise mechanisms by which MMPs are regulated and their interactions with various binding partners, it may be possible to block the deleterious functions of these enzymes without the concomitant loss of beneficial functions. This underscores the need for a greater investment than ever before in MMP biology and biochemistry. The next five years are expected to bring many exciting insights into the role of MMPs in development and human disease and may lead to even broader interest in what was once thought to be a highly specialized and restricted field.

Acknowledgements

The authors acknowledge support from National Institutes of Health award NIH AR47074.

Collagenolytic activity in amphibian tissues: a tissue culture assay. Gross J Lapiere CM Proc Natl Acad Sci USA 1962 48 1014 1022 13902219 Matrix metalloproteinases: a tail of a frog that became a prince. Brinckerhoff CE Matrisian LM Nat Rev Mol Cell Biol 2002 3 207 214 10.1038/nrm763 11994741 Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Coussens LM Fingleton B Matrisian LM Science 2002 295 2387 2392 10.1126/science.1067100 11923519 Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Vihinen P Kahari VM Int J Cancer 2002 99 157 166 10.1002/ijc.10329 11979428 New functions for the matrix metalloproteinases in cancer progression. Egeblad M Werb Z Nat Rev Cancer 2002 2 161 174 10.1038/nrc745 11990853 Matrix metalloproteinases in cancer. Itoh Y Nagase H Essays Biochem 2002 38 21 36 12463159 Structural analysis and promoter characterization of the human collagenase-3 gene (MMP13). Pendas AM Balbin M Llano E Jimenez MG Lopez-Otin C Genomics 1997 40 222 233 10.1006/geno.1996.4554 9119388 Matrix metalloproteinase degradation of extra-cellular matrix: biological consequences. Shapiro SD Curr Opin Cell Biol 1998 10 602 608 10.1016/S0955-0674(98)80035-5 9818170 Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation. Balbin M Fueyo A Knauper V Lopez JM Alvarez J Sanchez LM Quesada V Bordallo J Murphy G Lopez-Otin C J Biol Chem 2001 276 10253 10262 10.1074/jbc.M009586200 11113146 Cloning of three <it>Caenorhabditis elegans </it>genes potentially encoding novel matrix metalloproteinases. Wada K Sato H Kinoh H Kajita M Yamamoto H Seiki M Gene 1998 211 57 62 10.1016/S0378-1119(98)00076-6 9573338 Dm1-MMP, a matrix metalloproteinase from <it>Drosophila </it>with a potential role in extracellular matrix remodeling during neural development. Llano E Pendas AM Aza-Blanc P Kornberg TB Lopez-Otin C J Biol Chem 2000 275 35978 35985 10.1074/jbc.M006045200 10964925 Early expression of a collagenase-like hatching enzyme gene in the sea urchin embryo. Lepage T Gache C EMBO J 1990 9 3003 3012 2167841 A novel hydra matrix metalloproteinase (HMMP) functions in extracellular matrix degradation, morphogenesis and the maintenance of differentiated cells in the foot process. Leontovich AA Zhang J Shimokawa K Nagase H Sarras MP Jr Development 2000 127 907 920 10648248 Primary structure and expression of a gamete lytic enzyme in <it>Chlamydomonas reinhardtii </it>: similarity of functional domains to matrix metalloproteases. Kinoshita T Fukuzawa H Shimada T Saito T Matsuda Y Proc Natl Acad Sci USA 1992 89 4693 4687 49149 1584806 Sequencing and characterization of the soybean leaf metalloproteinase: structural and functional similarity to the matrix metalloproteinase family. McGeehan G Burkhart W Anderegg R Becherer JD Gillikin JW Graham JS Plant Physiol 1992 99 1179 1193 Matrix metalloproteinse homologues from <it>Arabidopsis thaliana</it>. Expression and activity. Maidment JM Moore D Murphy GP Clark IM J Biol Chem 1999 274 34706 34712 10.1074/jbc.274.49.34706 10574937 A matrix metalloproteinase expressed on the surface of invasive tumour cells. Sato H Takino T Okada Y Cao J Shinagawa A Yamamoto E Seiki M Nature 1994 370 61 65 10.1038/370061a0 8015608 Membrane type 4 matrix metalloproteinase (MT4-MMP, MMP-17) is a glycosylphosphatidylinositol-anchored proteinase. Itoh Y Kajita M Kinoh H Mori H Okada A Seiki M J Biol Chem 1999 274 34260 34266 10.1074/jbc.274.48.34260 10567400 CA-MMP: a matrix metalloproteinase with a novel cysteine array, but without the classic cysteine switch. Pei D FEBS Lett 1999 457 262 270 10.1016/S0014-5793(99)01046-7 10471791 Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Brooks PC Stromblad S Sanders LC von Schalscha TL Aimes RT Stetler-Stevenson WG Quigley JP Cheresh DA Cell 1996 85 683 693 8646777 EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface. Guo H Li R Zucker S Toole BP Cancer Res 2000 60 888 891 10706100 CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Yu WH Woessner JF Jr McNeish JD Stamenkovic I Genes Dev 2002 16 307 323 155329 11825873 10.1101/gad.925702 Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Li Q Park PW Wilson CL Parks WC Cell 2002 111 635 646 12464176 The metzincin-superfamily of zinc-peptidases. Bode W Grams F Reinemer P Gomis-Ruth FX Baumann U McKay DB Stocker W Adv Exp Med Biol 1996 389 1 11 8860988 Structural features of a superfamily of zinc-endopeptidases: the metzincins. Stocker W Bode W Curr Opin Struct Biol 1995 5 383 390 10.1016/0959-440X(95)80101-4 7583637 Extracellular matrix binding properties of recombinant fibronectin type II-like modules of human 72-kDa gelatinase/type IV collagenase. High affinity binding to native type I collagen but not native type IV collagen. Steffensen B Wallon UM Overall CM J Biol Chem 1995 270 11555 11566 10.1074/jbc.270.19.11555 7744795 The structural basis for the elastolytic activity of the 92-kDa and 72-kDa gelatinases. Role of the fibronectin type II-like repeats. Shipley JM Doyle GA Fliszar CJ Ye QZ Johnson LL Shapiro SD Welgus HG Senior RM J Biol Chem 1996 271 4335 4341 10.1074/jbc.271.8.4335 8626782 Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. Murphy G Nguyen Q Cockett MI Atkinson SJ Allan JA Knight CG Willenbrock F Docherty AJ J Biol Chem 1994 269 6632 6636 8120015 Identification and characterization of human endometase (matrix metalloproteinase-26) from endometrial tumor. Park HI Ni J Gerkema FE Liu D Belozerov VE Sang QX J Biol Chem 2000 275 20540 20544 10.1074/jbc.M002349200 10801841 Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. Velasco G Pendas AM Fueyo A Knauper V Murphy G Lopez-Otin C J Biol Chem 1999 274 4570 4576 10.1074/jbc.274.8.4570 9988691 Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Morgunova E Tuuttila A Bergmann U Isupov M Lindqvist Y Schneider G Tryggvason K Science 1999 284 1667 1670 10.1126/science.284.5420.1667 10356396 Engineering of selective TIMPs. Nagase H Meng Q Malinovskii V Huang W Chung L Bode W Maskos K Brew K Ann NY Acad Sci 1999 878 1 11 10415716 The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Van Wart HE Birkedal-Hansen H Proc Natl Acad Sci USA 1990 87 5578 5582 54368 2164689 Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. Sato H Kinoshita T Takino T Nakayama K Seiki M FEBS Lett 1996 393 101 104 10.1016/0014-5793(96)00861-7 8804434 Shedding of membrane type matrix metalloproteinase 5 by a furin-type convertase: a potential mechanism for down-regulation. Wang X Pei D J Biol Chem 2001 276 35953 35960 10.1074/jbc.M103680200 11470782 Activation of membrane-type matrix metalloproteinase 3 zymogen by the proprotein convertase furin in the trans-Golgi network. Kang T Nagase H Pei D Cancer Res 2002 62 675 681 11830519 Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Pei D Weiss SJ Nature 1995 375 244 247 10.1038/375244a0 7746327 Metalloproteinase inhibitors: biological actions and therapeutic opportunities. Baker AH Edwards DR Murphy G J Cell Sci 2002 115 3719 3727 10.1242/jcs.00063 12235282 Post-translational proteolytic processing of procollagen C-terminal proteinase enhancer releases a metalloproteinase inhibitor. Mott JD Thomas CL Rosenbach MT Takahara K Greenspan DS Banda MJ J Biol Chem 2000 275 1384 1390 10.1074/jbc.275.2.1384 10625689 The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Oh J Takahashi R Kondo S Mizoguchi A Adachi E Sasahara RM Nishimura S Imamura Y Kitayama H Alexander DB Cell 2001 107 789 800 11747814 Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Takahashi C Sheng Z Horan TP Kitayama H Maki M Hitomi K Kitaura Y Takai S Sasahara RM Horimoto A Proc Natl Acad Sci USA 1998 95 13221 13226 23764 9789069 10.1073/pnas.95.22.13221 TIMP-2 is required for efficient activation of proMMP-2 <it>in vivo</it>. Wang Z Juttermann R Soloway PD J Biol Chem 2000 275 26411 26415 10.1074/jbc.M001270200 10827175 The matrix metalloproteinase-14 (MMP-14) gene is structurally distinct from other MMP genes and is co-expressed with the TIMP-2 gene during mouse embryogenesis. Apte SS Fukai N Beier DR Olsen BR J Biol Chem 1997 272 25511 25517 10.1074/jbc.272.41.25511 9325265 Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. Knauper V Will H Lopez-Otin C Smith B Atkinson SJ Stanton H Hembry RM Murphy G J Biol Chem 1996 271 17124 17131 10.1074/jbc.271.29.17124 8663255 Regulation of membrane-type-1 matrix metalloproteinase activity by its cytoplasmic domain. Lehti K Valtanen H Wickstrom S Lohi J Keski-Oja J J Biol Chem 2000 275 15006 15013 10.1074/jbc.M910220199 10748199 Oligomerization through hemopexin and cytoplasmic domains regulates the activity and turnover of membrane-type 1 matrix metalloproteinase. Lehti K Lohi J Juntunen MM Pei D Keski-Oja J J Biol Chem 2002 277 8440 8448 10.1074/jbc.M109128200 11779859 Mutation analysis of membrane type-1 matrix metalloproteinase (MT1-MMP). The role of the cytoplasmic tail Cys(574), the active site Glu(240), and furin cleavage motifs in oligomerization, processing, and self-proteolysis of MT1-MMP expressed in breast carcinoma cells. Rozanov DV Deryugina EI Ratnikov BI Monosov EZ Marchenko GN Quigley JP Strongin AY J Biol Chem 2001 276 25705 25714 10.1074/jbc.M007921200 11335709 Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. Nakahara H Howard L Thompson EW Sato H Seiki M Yeh Y Chen WT Proc Natl Acad Sci USA 1997 94 7959 7964 21537 9223295 10.1073/pnas.94.15.7959 Localization of membrane-type 1 matrix metalloproteinase in caveolae membrane domains. Annabi B Lachambre M Bousquet-Gagnon N Page M Gingras D Beliveau R Biochem J 2001 353 547 553 10.1042/0264-6021:3530547 11171051 Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis. Jiang A Lehti K Wang X Weiss SJ Keski-Oja J Pei D Proc Natl Acad Sci USA 2001 98 13693 13698 61103 11698655 10.1073/pnas.241293698 Cytoplasmic tail-dependent internalization of membrane-type 1 matrix metalloproteinase is important for its invasion-promoting activity. Uekita T Itoh Y Yana I Ohno H Seiki M J Cell Biol 2001 155 1345 1356 10.1083/jcb.200108112 11756481 Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. Yang Z Strickland DK Bornstein P J Biol Chem 2001 276 8403 8408 10.1074/jbc.M008925200 11113133 Collagenase-3 binds to a specific receptor and requires the low density lipoprotein receptor-related protein for internalization. Barmina OY Walling HW Fiacco GJ Freije JM Lopez-Otin C Jeffrey JJ Partridge NC J Biol Chem 1999 274 30087 30093 10.1074/jbc.274.42.30087 10514495 Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors. Lovejoy B Welch AR Carr S Luong C Broka C Hendricks RT Campbell JA Walker KA Martin R Van Wart H Browner MF Nat Struct Biol 1999 6 217 221 10.1038/6657 10074939 High affinity binding of latent matrix metalloproteinase-9 to the alpha2(IV) chain of collagen IV. Olson MW Toth M Gervasi DC Sado Y Ninomiya Y Fridman R J Biol Chem 1998 273 10672 10681 10.1074/jbc.273.17.10672 9553130 Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. Suzuki M Raab G Moses MA Fernandez CA Klagsbrun M J Biol Chem 1997 272 31730 31737 10.1074/jbc.272.50.31730 9395517 Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. Imai K Hiramatsu A Fukushima D Pierschbacher MD Okada Y Biochem J 1997 322 809 814 9148753 The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. Whitelock JM Murdoch AD Iozzo RV Underwood PA J Biol Chem 1996 271 10079 10086 10.1074/jbc.271.17.10079 8626565 Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. Manes S Mira E Barbacid MM Cipres A Fernandez-Resa P Buesa JM Merida I Aracil M Marquez G Martinez AC J Biol Chem 1997 272 25706 25712 10.1074/jbc.272.41.25706 9325295 Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. Fowlkes JL Thrailkill KM Serra DM Suzuki K Nagase H Prog Growth Factor Res 1995 6 255 263 8817668 Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. Fowlkes JL Enghild JJ Suzuki K Nagase H J Biol Chem 1994 269 25742 25746 7523391 Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. Noe V Fingleton B Jacobs K Crawford HC Vermeulen S Steelant W Bruyneel E Matrisian LM Mareel M J Cell Sci 2001 114 111 118 11112695 Cleavage and shedding of E-cadherin after induction of apoptosis. Steinhusen U Weiske J Badock V Tauber R Bommert K Huber O J Biol Chem 2001 276 4972 4980 10.1074/jbc.M006102200 11076937 Metalloproteinase-mediated regulation of L-selectin levels on leucocytes. Preece G Murphy G Ager A J Biol Chem 1996 271 11634 11640 10.1074/jbc.271.20.11634 8662605 Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent. Asamoto M Hokaiwado N Cho YM Takahashi S Ikeda Y Imaida K Shirai T Cancer Res 2001 61 4693 4700 11406539 Functional distinction between CXC chemokines, interleukin-8 (IL-8), and growth related oncogene (GRO)alpha in neutrophil infiltration. Fujiwara K Matsukawa A Ohkawara S Takagi K Yoshinaga M Lab Invest 2002 82 15 23 11796822 Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. McQuibban GA Butler GS Gong JH Bendall L Power C Clark-Lewis I Overall CM J Biol Chem 2001 276 43503 43508 10.1074/jbc.M107736200 11571304 Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Levi E Fridman R Miao HQ Ma YS Yayon A Vlodavsky I Proc Natl Acad Sci USA 1996 93 7069 7074 38937 8692946 10.1073/pnas.93.14.7069 Defensins and host defense. Ganz T Science 1999 286 420 421 10.1126/science.286.5439.420 10577203 Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Wilson CL Ouellette AJ Satchell DP Ayabe T Lopez-Boado YS Stratman JL Hultgren SJ Matrisian LM Parks WC Science 1999 286 113 117 10.1126/science.286.5437.113 10506557 Selective cleavage of human IgG by the matrix metalloproteinases, matrilysin and stromelysin. Gearing AJ Thorpe SJ Miller K Mangan M Varley PG Dudgeon T Ward G Turner C Thorpe R Immunol Lett 2002 81 41 48 10.1016/S0165-2478(01)00333-9 11841844 Digestion of C1q collagen-like domain with MMPs-1,-2,-3, and -9 further defines the sequence involved in the stimulation of neutrophil superoxide production. Ruiz S Henschen-Edman AH Nagase H Tenner AJ J Leukoc Biol 1999 66 416 422 10496311 Cooperation of C1q receptors and integrins in C1q-mediated endothelial cell adhesion and spreading. Feng X Tonnesen MG Peerschke EI Ghebrehiwet B J Immunol 2002 168 2441 2448 11859136 The hemopexin-like C-terminal domain of membrane type 1 matrix metalloproteinase regulates proteolysis of a multifunctional protein, gC1qR. Rozanov DV Ghebrehiwet B Postnova TI Eichinger A Deryugina EI Strongin AY J Biol Chem 2002 277 9318 9325 10.1074/jbc.M110711200 11773076 Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. Martignetti JA Aqeel AA Sewairi WA Boumah CE Kambouris M Mayouf SA Sheth KV Eid WA Dowling O Harris J Nat Genet 2001 28 261 265 10.1038/90100 11431697 MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Holmbeck K Bianco P Caterina J Yamada S Kromer M Kuznetsov SA Mankani M Robey PG Poole AR Pidoux I Cell 1999 99 81 92 10520996 Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Zhou Z Apte SS Soininen R Cao R Baaklini GY Rauser RW Wang J Cao Y Tryggvason K Proc Natl Acad Sci USA 2000 97 4052 4057 18145 10737763 10.1073/pnas.060037197 Duplication of a genomic region containing the Cdc2L1-2 and MMP21-22 genes on human chromosome 1p36.3 and their linkage to D1Z2. Gururajan R Lahti JM Grenet J Easton J Gruber I Ambros PF Kidd VJ Genome Res 1998 8 929 939 9750192 A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Zhu Y Spitz MR Lei L Mills GB Wu X Cancer Res 2001 61 7825 7829 11691799 Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. Ghilardi G Biondi ML Mangoni J Leviti S DeMonti M Guagnellini E Scorza R Clin Cancer Res 2001 7 2344 2346 11489811 A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Rutter JL Mitchell TI Buttice G Meyers J Gusella JF Ozelius LJ Brinckerhoff CE Cancer Res 1998 58 5321 5325 9850057 MMP1 and MMP3 polymorphisms in promoter regions and cancer. Biondi ML Turri O Leviti S Seminati R Cecchini F Bernini M Ghilardi G Guagnellini E Clin Chem 2000 46 2023 2024 11106348 Matrix metalloproteinases in lung biology. Parks WC Shapiro SD Respir Res 2001 2 10 19 59564 11686860 10.1186/rr33 Protease degradomics: a new challenge for proteomics. Lopez-Otin C Overall CM Nat Rev Mol Cell Biol 2002 3 509 519 10.1038/nrm858 12094217 Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Bergers G Brekken R McMahon G Vu TH Itoh T Tamaki K Tanzawa K Thorpe P Itohara S Werb Z Hanahan D Nat Cell Biol 2000 2 737 744 10.1038/35036374 11025665 Experimental metastasis is suppressed in MMP-9-deficient mice. Itoh T Tanioka M Matsuda H Nishimoto H Yoshioka T Suzuki R Uehira M Clin Exp Metastasis 1999 17 177 181 10.1023/A:1006603723759 10411111 Stromelysin-1 regulates adipogenesis during mammary gland involution. Alexander CM Selvarajan S Mudgett J Werb Z J Cell Biol 2001 152 693 703 10.1083/jcb.152.4.693 11266461 Impaired wound contraction in stromelysin-1-deficient mice. Bullard KM Lund L Mudgett JS Mellin TN Hunt TK Murphy B Ronan J Werb Z Banda MJ Ann Surg 1999 230 260 265 10.1097/00000658-199908000-00017 10450741 Matrix metalloproteinase deficiencies affect contact hypersensitivity: stromelysin-1 deficiency prevents the response and gelatinase B deficiency prolongs the response. Wang M Qin X Mudgett JS Ferguson TA Senior RM Welgus HG Proc Natl Acad Sci USA 1999 96 6885 6889 22011 10359808 10.1073/pnas.96.12.6885 Matrix metalloproteinase-3-dependent generation of a macrophage chemoattractant in a model of herniated disc resorption. Haro H Crawford HC Fingleton B MacDougall JR Shinomiya K Spengler DM Matrisian LM J Clin Invest 2000 105 133 141 10642591 Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Wilson CL Heppner KJ Labosky PA Hogan BL Matrisian LM Proc Natl Acad Sci USA 1997 94 1402 1407 19803 9037065 10.1073/pnas.94.4.1402 Matrilysin expression and function in airway epithelium. Dunsmore SE Saarialho-Kere UK Roby JD Wilson CL Matrisian LM Welgus HG Parks WC J Clin Invest 1998 102 1321 1331 9769324 The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Powell WC Fingleton B Wilson CL Boothby M Matrisian LM Curr Biol 1999 9 1441 1447 10.1016/S0960-9822(00)80113-X 10607586 Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. Haro H Crawford HC Fingleton B Shinomiya K Spengler DM Matrisian LM J Clin Invest 2000 105 143 150 10642592 MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Coussens LM Tinkle CL Hanahan D Werb Z Cell 2000 103 481 490 11081634 MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Vu TH Shipley JM Bergers G Berger JE Helms JA Hanahan D Shapiro SD Senior RM Werb Z Cell 1998 93 411 422 9590175 Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. Engsig MT Chen QJ Vu TH Pedersen AC Therkidsen B Lund LR Henriksen K Lenhard T Foged NT Werb Z Delaisse JM J Cell Biol 2000 151 879 889 10.1083/jcb.151.4.879 11076971 A critical role for neutrophil elastase in experimental bullous pemphigoid. Liu Z Shapiro SD Zhou X Twining SS Senior RM Giudice GJ Fairley JA Diaz LA J Clin Invest 2000 105 113 123 10619867 Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. Pyo R Lee JK Shipley OJM Curci JA Mao D Ziporin SJ Ennis TL Shapiro SD Senior RM Thompson RW J Clin Invest 2000 105 1641 1649 10841523 Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. Ducharme A Frantz S Aikawa M Rabkin E Lindsey M Rohde LE Schoen FJ Kelly RA Werb Z Libby P Lee RT J Clin Invest 2000 106 55 62 10880048 Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Heymans S Luttun A Nuyens D Theilmeier G Creemers E Moons L Dyspersin GD Cleutjens JP Shipley M Angellilo A Nat Med 1999 5 1135 1142 10.1038/13459 10502816 Matrix metalloproteinase 9 protects mice from anti-glomerular basement membrane nephritis through its fibrinolytic activity. Lelongt B Bengatta S Delauche M Lund LR Werb Z Ronco PM J Exp Med 2001 193 793 802 10.1084/jem.193.7.793 11283152 Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Galis ZS Johnson C Godin D Magid R Shipley JM Senior RM Ivan E Circ Res 2002 91 852 859 10.1161/01.RES.0000041036.86977.14 12411401 Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Cho A Reidy MA Circ Res 2002 91 845 851 10.1161/01.RES.0000040420.17366.2E 12411400 Matrix metalloproteinase-9 deficiency impairs cellular infiltration and bronchial hyperresponsiveness during allergen-induced airway inflammation. Cataldo DD Tournoy KG Vermaelen K Munaut C Foidart JM Louis R Noel A Pauwels RA Am J Pathol 2002 161 491 498 12163374 Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Heissig B Hattori K Dias S Friedrich M Ferris B Hackett NR Crystal RG Besmer P Lyden D Moore MA Werb Z Rafii S Cell 2002 109 625 637 12062105 Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. Romanic AM Harrison SM Bao W Burns-Kurtis CL Pickering S Gu J Grau E Mao J Sathe GM Ohlstein EH Yue TL Cardiovasc Res 2002 54 549 558 10.1016/S0008-6363(02)00254-7 12031700 <it>In vivo</it> evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. Masson R Lefebvre O Noel A Fahime ME Chenard MP Wendling C Kebers F LeMeur M Dierich A Foidart JM Basset P Rio MC J Cell Biol 1998 140 1535 1541 10.1083/jcb.140.6.1535 9508784 High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Boulay A Masson R Chenard MP El Fahime M Cassard L Bellocq JP Sautes-Fridman C Basset P Rio MC Cancer Res 2001 61 2189 2193 11280785 Accelerated neointima formation after vascular injury in mice with stromelysin-3 (MMP-11) gene inactivation. Lijnen HR Van Hoef B Vanlinthout I Verstreken M Rio MC Collen D Arterioscler Thromb Vasc Biol 1999 19 2863 2870 10591662 Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Hautamaki RD Kobayashi DK Senior RM Shapiro SD Science 1997 277 2002 2004 10.1126/science.277.5334.2002 9302297 How matrix metalloproteinases regulate cell behavior. Sternlicht MD Werb Z Annu Rev Cell Dev Biol 2001 17 463 516 10.1146/annurev.cellbio.17.1.463 11687497